[18F]AlF-OC
Atherosclerotic Cardiovascular Disease
Explore 16 assets in Atherosclerotic Cardiovascular Disease →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Universitaire Ziekenhuizen KU Leuven
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Atherosclerotic Cardiovascular Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [18F]AlF-OC (this asset) | Universitaire Ziekenhuizen KU Leuven | P2 | CCC · 53 |
| Eicosapentaenoic Acid Ethyl Ester | Kobe University | P4 | BB |
| Umbellatine | China National Center for Cardiovascular Diseases | P4 | BB |
| Maridebart Cafraglutide | Amgen | P3 | B |
| Inclisiran | Novartis Pharmaceuticals | P3 | B |
| Retatrutide | Eli Lilly and Company | P3 | B |
| Tirzepatide | Brigham and Women's Hospital | P4 | B |
| Orforglipron | Eli Lilly and Company | P3 | B |
| Semaglutide | Brigham and Women's Hospital | Unk | D |
+8 more in the Atherosclerotic Cardiovascular Disease cohort
Other indications for [18F]AlF-OC
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P2 | CCC · 53 |
| Carotid Stenosis | — | P2 | CCC · 53 |
| Atherosclerosis | — | P2 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [18F]AlF-OC in Atherosclerotic Cardiovascular Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/18falf-oc-atherosclerotic-cardiovascular-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →